French biotech stock soars 31% after new data on experimental medicine
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease, clawing back heavy losses from earlier in the month when the same trial had investors questioning the future of the drug. Shares gained nearly 1,700% in 2025 but had fallen 14% year-to date coming into Tuesday trading. The stock has yet to recover fully from the drop earlier this month when it traded above 111 euros ($127) a share.
- ▪Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease, clawing back heavy losses from earlier in the month when the same trial had investors questioning the future of the drug
- ▪Shares gained nearly 1,700% in 2025 but had fallen 14% year-to date coming into Tuesday trading.
- ▪The stock has yet to recover fully from the drop earlier this month when it traded above 111 euros ($127) a share.
CNBC — Top files mainly under finance. We currently carry 510 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | CNBC — Top |
| Canonical URL | https://www.cnbc.com/2026/06/30/abivax-stock-trial-data-biotech-obefazimod.html |
| Publication time | Tue, 30 Jun 2026 08:05:10 GMT |
| Retrieval time | 2026-06-30T08:09:23.969Z |
| Last seen | 2026-06-30T08:09:23.969Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | Qi1XC5xSqoQb |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Shares of French biotech company Abivax soared Tuesday after it released fresh data on its lead drug for bowel disease, clawing back heavy losses from earlier in the month when the same trial had investors questioning the future of the drug. Abivax stock was last trading up 31%. It came after it crashed around 44% on June 2, following a data set that showed there were cancer cases among patients taking the highest dose of its experimental medicine obefazimod.Additional data on the late-stage clinical trial, released late on Monday, showed that malignancies were in line with expected background rates.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at CNBC — Top.
Discussion
0 commentsMore from CNBC — Top
